CompletedPhase 4NCT00906880

Clinical Study to Assess the Tolerability, Feasibility and Effectiveness of Nifurtimox and Eflornithine (NECT) for the Treatment of Trypanosoma Brucei Gambiense Human African Trypanosomiasis (HAT) in the Meningo-encephalitic Phase

Studying African trypanosomiasis

Last synced from ClinicalTrials.gov May 3, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Drugs for Neglected Diseases
Principal Investigator: Johannes Blum, MD
Swiss Tropical & Public Health Institute
Intervention: Nifurtimox-Eflronithine Combination Treatment (NECT)(drug)
Enrollment: 630 enrolled
Eligibility: All sexes
Timeline: 2009 – 2013

Study locations (6)

HGR (General Reference Hospital) Bandundu, Bandundu, Bandundu, Republic of the Congo
HGR (General Reference Hospital) Kwamouth, Kwamouth, Bandundu, Republic of the Congo
HGR (General Reference Hospital) Yasa Bonga, Yasa Bonga, Bandundu, Republic of the Congo
CDTC (Centre de Dépistage, Traitement et Contrôle) Katanda, Katanda, East Kasai, Republic of the Congo
CRT (Centre de Réference et de Traitement) Dipumba, Dipumba general hospital, Mbuji Mayi, East Kasai, Republic of the Congo
HGR (General Reference Hospital) Ngandajika, Ngandajika, East Kasai, Republic of the Congo

Collaborators

Ministry of Public Health, Democratic Republic of the Congo · Swiss Tropical & Public Health Institute

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00906880 on ClinicalTrials.gov

Other trials for African trypanosomiasis

Additional recruiting or active studies for the same condition.

See all trials for African trypanosomiasis →

← Back to all trials